scholarly journals Renal Cell Carcinoma in End-Stage Renal Disease

10.5772/59378 ◽  
2015 ◽  
Author(s):  
Yasukazu Nakanishi ◽  
Fumitaka Koga ◽  
Hiroshi Fukushima ◽  
Toru Motoi ◽  
Ken-ichi Tobisu
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Disease ◽  
Cell Carcinoma ◽  
End Stage Renal Disease ◽  
Renal Cell ◽  
Stage Renal Disease ◽  
End Stage

Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis

2010 ◽  
Vol 105 (5) ◽  
pp. 620-627 ◽  
Author(s):  
Mohammed A.A.M. Nouh ◽  
Naoto Kuroda ◽  
Motoki Yamashita ◽  
Yushi Hayashida ◽  
Toshifumi Yano ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Disease ◽  
Cell Carcinoma ◽  
End Stage Renal Disease ◽  
Renal Cell ◽  
Histological Type ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Transperitoneal laparoscopic right radical nephrectomy for renal cell carcinoma and end-stage renal disease: a case report

Cases Journal ◽  
2009 ◽  
Vol 2 (1) ◽  
Author(s):  
Christoforos Kosmıdis ◽  
Christoforos Efthimiadis ◽  
Georgios Anthimidis ◽  
Marios Grigoriou ◽  
Kalliopi Vasiliadou ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Renal Disease ◽  
Cell Carcinoma ◽  
End Stage Renal Disease ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Jawaher Ansari ◽  
Muhammad Ali ◽  
Ashraf Farrag ◽  
Arwa M. Ali ◽  
Abdulaziz Alhamad
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Disease ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
End Stage Renal Disease ◽  
Renal Cell ◽  
Pharmacokinetic Data ◽  
Management Options ◽  
Stage Renal Disease ◽  
End Stage

Treatment of patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD) on dialysis poses a therapeutic challenge, particularly as this patient group was excluded from the pivotal clinical trials. In addition, there is uncertainty regarding drug dosing/pharmacokinetics, lack of safety and efficacy data, and potential for increased toxicity when using targeted therapy or immunotherapy for the management of patients with mRCC on dialysis. Nivolumab, an anti-programmed death-1 immune checkpoint inhibitor antibody, is indicated for the treatment of patients with mRCC who have received prior antiangiogenic therapy. Given the above-mentioned uncertainties, clinicians may be reluctant to use nivolumab for this patient population, leading to potential denial of life-prolonging medications. We report the case of a 72-year-old gentleman with mRCC and ESRD on dialysis who received second-line nivolumab therapy and achieved an excellent symptomatic and radiological response, remaining progression-free for over 22 months. In addition, we have reviewed the pharmacokinetic data and published retrospective case studies to review the management options for patients with mRCC and ESRD on dialysis.

scholarly journals Genomic profiling of renal cell carcinoma in patients with end-stage renal disease

2012 ◽  
Vol 103 (3) ◽  
pp. 569-576 ◽  
Author(s):  
Toru Inoue ◽  
Keiko Matsuura ◽  
Taichiro Yoshimoto ◽  
Lam Tung Nguyen ◽  
Yoshiyuki Tsukamoto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Renal Disease ◽  
Cell Carcinoma ◽  
End Stage Renal Disease ◽  
Renal Cell ◽  
Genomic Profiling ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document